Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data

Pfizer Inc. (NYSE:PFE) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In.

On March 24, Guggenheim Partners raised its price recommendation on Pfizer Inc. (NYSE:PFE) to $36 from $35. It reiterated a Buy rating on the shares. The analyst pointed to upcoming data from the MEVPRO-1 Phase 3 trial of mevrometostat in second-line and later mCRPC, expected in the second half of 2026. Based on that setup, the firm sees about $2 per share upside if the trial succeeds, compared with roughly $1 downside if it does not.

On March 23, Reuters reported that Pfizer and Valneva said their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even though it missed its main goal. Pfizer said the overall results still support confidence in the vaccine and confirmed plans to move forward with regulatory submissions. The vaccine showed 73.2% efficacy starting 28 days after the fourth dose in reducing confirmed Lyme disease cases compared to placebo.

The companies explained that the trial was designed to demonstrate a confidence interval of at least 20%. In the first analysis, that figure came in at 15.8%, mainly because fewer Lyme cases than expected occurred during the study, which limited the dataset. A second planned analysis, measured one day after the fourth dose instead of 28 days later, met the required threshold, according to the companies.

Pfizer Inc. (NYSE:PFE) is a research-driven global biopharmaceutical company focused on discovering, developing, manufacturing, and distributing medicines worldwide.

READ NEXT: 15 Dividend Stocks to Buy for Steady Income and Dividend Kings and Aristocrats List: 32 Biggest Stocks

Disclosure: None. Follow Insider Monkey on Google News.